- Technology from Johns Hopkins University’s Wilmer Eye Institute; co-founders are world renowned ophthalmology and micro particle formulation experts
- company in preclinical development with superior extended release/durable formulations for ocular diseases
- Co-investors: Maryland Venture Fund
- Technology from Kyoto University and Nobel-prize winning work of Shinya Yamanaka
- Commercializing a personalized, regenerative medicine platform utilizing incudes pluripotent stem cells, or iPS cells
- Co-investors: Mountain Group Capital, KTB Ventures, Harris & Harris
- Technology from Georgia Tech and Emory, this clinical-stage ophthalmic pharmaceutical company is utilizing a proprietary, disruptive microinjection platform to deliver drugs via the suprachoroidal space for sight-threatening diseases
G1 Therapeutics, Inc.
- Technology from UNC-Chapel Hill’s comprehensive cancer center, this clinical-stage company is built on a robust platform of potent,
selective CDK4/6 inhibitors to protect bone marrow from chemotherapy and ionizing radiation
Lysosomal Therapeutics Inc.
- Technology from Mass General and Harvard, this pre-clinical biotech company is developing allosteric glucocerebrosidase activators to restore lysosomal function in human neurons for treatment of Gaucher’s and Parkinson’s Diseases
- Technology from Cornell University, this company is developing a novel chemistry platform focused on developing small molecule,
self-assembling pharmacophore pairs to intervene at dicult intra-cellular protein targets
- Technology from Dr. George Church’s lab at Harvard, this company is developing an open-source platform to manage “big” genomic data; focused on increasing productivity and lowering costs for storing, organizing, analyzing and sharing NGS data
- This company is developing a neuromodulation device for patients suffering from heart failure; focused on the select stimulation of target nerves to impact hemodynamics, and deliver exceptional patient outcomes and positive healthcare economics